BCTX logo

BriaCell Therapeutics (BCTX) Cash From Operations

Annual CFO

-$24.13 M
-$381.20 K-1.61%

01 July 2024

BCTX Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFO

-$4.04 M
+$1.05 M+20.62%

01 July 2024

BCTX Quarterly CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFO

-$24.13 M
+$6.88 M+22.20%

01 July 2024

BCTX TTM CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

BCTX Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-1.6%+46.9%+13.2%
3 y3 years-211.3%-126.9%-154.7%
5 y5 years-481.7%-402.8%-526.0%

BCTX Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-211.3%at low-126.9%+63.0%-154.7%+22.8%
5 y5 years-1805.8%at low-6781.6%+63.0%-4528.1%+22.8%
alltimeall time<-9999.0%at low-6781.6%+63.0%<-9999.0%+22.8%

BriaCell Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
July 2024
-$24.13 M(+1.6%)
-$4.04 M(-20.6%)
-$24.13 M(-22.2%)
Apr 2024
-
-$5.08 M(-31.3%)
-$31.01 M(-0.8%)
Jan 2024
-
-$7.40 M(-2.7%)
-$31.26 M(+12.4%)
Oct 2023
-
-$7.61 M(-30.3%)
-$27.81 M(+17.1%)
July 2023
-$23.74 M(+90.2%)
-$10.92 M(+104.8%)
-$23.74 M(+47.0%)
Apr 2023
-
-$5.33 M(+34.9%)
-$16.15 M(+3.2%)
Jan 2023
-
-$3.95 M(+11.6%)
-$15.64 M(+9.8%)
Oct 2022
-
-$3.54 M(+6.5%)
-$14.25 M(+14.1%)
July 2022
-$12.48 M(+61.1%)
-$3.33 M(-31.1%)
-$12.48 M(+12.4%)
Apr 2022
-
-$4.82 M(+88.7%)
-$11.10 M(-6.4%)
Jan 2022
-
-$2.56 M(+43.7%)
-$11.87 M(+25.3%)
Oct 2021
-
-$1.78 M(-8.6%)
-$9.47 M(+22.2%)
July 2021
-$7.75 M(+512.2%)
-$1.95 M(-65.2%)
-$7.75 M(+25.0%)
Apr 2021
-
-$5.59 M(+3432.2%)
-$6.20 M(+1019.4%)
Jan 2021
-
-$158.20 K(+172.3%)
-$554.10 K(+6.3%)
Oct 2020
-
-$58.10 K(-85.4%)
-$521.30 K(-58.8%)
July 2020
-$1.27 M(-69.5%)
-$398.20 K(-759.3%)
-$1.27 M(-28.6%)
Apr 2020
-
$60.40 K(-148.2%)
-$1.77 M(-49.4%)
Jan 2020
-
-$125.40 K(-84.4%)
-$3.51 M(-9.0%)
Oct 2019
-
-$802.70 K(-11.4%)
-$3.85 M(-7.1%)
July 2019
-$4.15 M(+9.0%)
-$906.10 K(-45.8%)
-$4.15 M(-1.2%)
Apr 2019
-
-$1.67 M(+254.1%)
-$4.20 M(+19.2%)
Jan 2019
-
-$472.40 K(-56.9%)
-$3.52 M(-8.9%)
Oct 2018
-
-$1.10 M(+14.4%)
-$3.87 M(+1.6%)
July 2018
-$3.81 M(+147.9%)
-$958.00 K(-3.8%)
-$3.81 M(+25.2%)
Apr 2018
-
-$996.10 K(+22.0%)
-$3.04 M(+10.3%)
Jan 2018
-
-$816.70 K(-21.1%)
-$2.76 M(+22.7%)
Oct 2017
-
-$1.03 M(+435.9%)
-$2.25 M(+46.4%)
July 2017
-$1.54 M(+28.0%)
-$193.10 K(-72.9%)
-$1.54 M(-6.0%)
Apr 2017
-
-$713.00 K(+132.3%)
-$1.63 M(+28.6%)
Jan 2017
-
-$306.90 K(-4.8%)
-$1.27 M(+4.1%)
Oct 2016
-
-$322.30 K(+10.8%)
-$1.22 M(+1.7%)
July 2016
-$1.20 M(+28.2%)
-$290.90 K(-16.7%)
-$1.20 M(+6.8%)
Apr 2016
-
-$349.40 K(+36.1%)
-$1.12 M(+4.4%)
Jan 2016
-
-$256.80 K(-15.0%)
-$1.08 M(-12.7%)
Oct 2015
-
-$302.00 K(+40.5%)
-$1.23 M(+31.7%)
DateAnnualQuarterlyTTM
July 2015
-$935.30 K(+157.0%)
-$214.90 K(-28.8%)
-$935.20 K(+9.8%)
Apr 2015
-
-$301.70 K(-27.0%)
-$851.40 K(+30.5%)
Jan 2015
-
-$413.10 K(+7410.9%)
-$652.20 K(+118.1%)
Oct 2014
-
-$5500.00(-95.8%)
-$299.00 K(-17.8%)
July 2014
-$364.00 K(-1.2%)
-$131.10 K(+27.9%)
-$363.90 K(-11.3%)
Apr 2014
-
-$102.50 K(+71.1%)
-$410.40 K(+2.1%)
Jan 2014
-
-$59.90 K(-14.9%)
-$402.10 K(+7.9%)
Oct 2013
-
-$70.40 K(-60.4%)
-$372.80 K(+1.2%)
July 2013
-$368.50 K(-3.4%)
-$177.60 K(+88.5%)
-$368.50 K(+25.3%)
Apr 2013
-
-$94.20 K(+207.8%)
-$294.00 K(-11.6%)
Jan 2013
-
-$30.60 K(-53.7%)
-$332.60 K(-16.4%)
Oct 2012
-
-$66.10 K(-35.9%)
-$398.00 K(+4.3%)
July 2012
-$381.50 K(-44.8%)
-$103.10 K(-22.4%)
-$381.60 K(-20.2%)
Apr 2012
-
-$132.80 K(+38.3%)
-$477.90 K(-20.4%)
Jan 2012
-
-$96.00 K(+93.2%)
-$600.30 K(-12.8%)
Oct 2011
-
-$49.70 K(-75.1%)
-$688.70 K(-0.3%)
July 2011
-$690.80 K(+123.3%)
-$199.40 K(-21.9%)
-$690.80 K(+34.8%)
Apr 2011
-
-$255.20 K(+38.4%)
-$512.40 K(+34.7%)
Jan 2011
-
-$184.40 K(+256.0%)
-$380.40 K(+40.7%)
Oct 2010
-
-$51.80 K(+146.7%)
-$270.40 K(-12.6%)
July 2010
-$309.40 K(+120.1%)
-$21.00 K(-83.0%)
-$309.40 K(-6.8%)
Apr 2010
-
-$123.20 K(+65.6%)
-$332.00 K(+63.1%)
Jan 2010
-
-$74.40 K(-18.1%)
-$203.60 K(+35.6%)
Oct 2009
-
-$90.80 K(+108.3%)
-$150.20 K(+6.9%)
July 2009
-$140.60 K(+60.9%)
-$43.60 K(-938.5%)
-$140.50 K(-1.4%)
Apr 2009
-
$5200.00(-124.8%)
-$142.50 K(-17.6%)
Jan 2009
-
-$21.00 K(-74.1%)
-$172.90 K(+6.8%)
Oct 2008
-
-$81.10 K(+77.9%)
-$161.90 K(+85.0%)
July 2008
-$87.40 K(-0.5%)
-$45.60 K(+81.0%)
-$87.50 K(+30.6%)
Apr 2008
-
-$25.20 K(+152.0%)
-$67.00 K(+18.4%)
Jan 2008
-
-$10.00 K(+49.3%)
-$56.60 K(-17.0%)
Oct 2007
-
-$6700.00(-73.3%)
-$68.20 K(-22.2%)
July 2007
-$87.80 K(<-9900.0%)
-$25.10 K(+69.6%)
-$87.70 K(+40.1%)
Apr 2007
-
-$14.80 K(-31.5%)
-$62.60 K(+31.0%)
Jan 2007
-
-$21.60 K(-17.6%)
-$47.80 K(+82.4%)
Oct 2006
-
-$26.20 K
-$26.20 K
July 2006
$0.00
-
-

FAQ

  • What is BriaCell Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for BriaCell Therapeutics?
  • What is BriaCell Therapeutics annual CFO year-on-year change?
  • What is BriaCell Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for BriaCell Therapeutics?
  • What is BriaCell Therapeutics quarterly CFO year-on-year change?
  • What is BriaCell Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for BriaCell Therapeutics?
  • What is BriaCell Therapeutics TTM CFO year-on-year change?

What is BriaCell Therapeutics annual cash flow from operations?

The current annual CFO of BCTX is -$24.13 M

What is the all time high annual CFO for BriaCell Therapeutics?

BriaCell Therapeutics all-time high annual cash flow from operations is $0.00

What is BriaCell Therapeutics annual CFO year-on-year change?

Over the past year, BCTX annual cash flow from operations has changed by -$381.20 K (-1.61%)

What is BriaCell Therapeutics quarterly cash flow from operations?

The current quarterly CFO of BCTX is -$4.04 M

What is the all time high quarterly CFO for BriaCell Therapeutics?

BriaCell Therapeutics all-time high quarterly cash flow from operations is $60.40 K

What is BriaCell Therapeutics quarterly CFO year-on-year change?

Over the past year, BCTX quarterly cash flow from operations has changed by +$3.57 M (+46.93%)

What is BriaCell Therapeutics TTM cash flow from operations?

The current TTM CFO of BCTX is -$24.13 M

What is the all time high TTM CFO for BriaCell Therapeutics?

BriaCell Therapeutics all-time high TTM cash flow from operations is -$26.20 K

What is BriaCell Therapeutics TTM CFO year-on-year change?

Over the past year, BCTX TTM cash flow from operations has changed by +$3.68 M (+13.24%)